How to Test Human-Specific Combination Immunotherapies In Vivo

Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.

Enhancing anti-tumour efficacy with immunotherapy combinations - The Lancet

The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma in: Neurosurgical Focus Volume 50 Issue 2 (2021) Journals

In vivo gene immunotherapy for cancer

Role of NK cells to treat B-Cell Lymphoma

The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer - Cytotherapy

Beginners Guide to PBMC Humanized Tumor Models

Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12

Frontiers Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research

Humanized Mouse Model Head to Head: hPBMC vs hCD34+

What Are Neoantigens?

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Combining Nanomedicine and Immunotherapy

Introduction to Skin Cells for Toxicity Testing

Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine